About argenx SE - American Depositary Shares (ARGX)
Argenx is a biotechnology company focused on developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company utilizes its proprietary platform to discover and create monoclonal antibodies that target specific proteins in the immune system to modulate its response. By exploring a diverse pipeline of clinical-stage candidates, Argenx aims to address unmet medical needs and improve patient outcomes through its cutting-edge approaches in immunology and therapeutic development. Read More
argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
The study evaluated e
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized basis producing an average annual return of 25.33%. Currently, argenx has a market capitalization of $60.86 billion.
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized basis producing an average annual return of 22.73%. Currently, argenx has a market capitalization of $54.18 billion.
argenex (NASDAQ:ARGX) said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for autoimmune diseases including vitiligo and celiac disease.
Under the agreement, argenex will commence
argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.
argenex (NASDAQ:ARGX) reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, as well as early momentum from a newly expanded label in generalized myasthenia gr
July 16, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update.
Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the
argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
